Can I Get Weight Loss Shots on Medicaid in 2026? State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only 14 states cover FDA-approved weight loss medications (Wegovy, Zepbound) through Medicaid as of April 2026, and all require prior authorization with strict BMI and comorbidity criteria
• Federal law prohibits Medicaid from covering medications "used for weight loss or weight gain" unless treating an underlying medical condition, creating a coverage gap for obesity treatment
• Compounded semaglutide and tirzepatide are typically not covered by Medicaid but cost $179 to $279 monthly through cash-pay telehealth platforms
• Medicaid covers the same medications (Ozempic, Mounjaro) for type 2 diabetes in all 50 states, creating a diagnosis-dependent coverage split

Direct answer (40-60 words)

Medicaid coverage for weight loss shots depends entirely on your state. Fourteen states cover FDA-approved medications like Wegovy or Zepbound for obesity as of 2026, but all require prior authorization, BMI over 30 (or 27 with comorbidities), and documented lifestyle intervention attempts. The remaining 36 states exclude weight loss medications from their formularies.

Table of contents

1. The federal Medicaid exclusion that blocks most coverage
2. The 14 states that cover weight loss medications (and their requirements)
3. The 36 states that don't cover weight loss shots
4. Why the same medication gets covered for diabetes but not obesity
5. Real prior authorization scenarios from covered states
6. Income limits and Medicaid expansion status by state
7. The compounded semaglutide alternative for Medicaid patients
8. Manufacturer patient assistance programs (and why most exclude Medicaid)
9. What most articles get wrong about Medicaid obesity coverage
10. The decision tree: your actual options by state and diagnosis
11. FAQ
12. Sources

The federal Medicaid exclusion that blocks most coverage

The barrier to Medicaid coverage for weight loss shots isn't medical. It's statutory.

The Social Security Act, Section 1927(d)(2), explicitly excludes medications "used for weight loss or weight gain" from mandatory Medicaid coverage. This provision dates to 1993, when Congress wanted to prevent Medicaid spending on what it categorized as "lifestyle drugs" alongside fertility treatments and cosmetic medications.

States can choose to cover excluded medications using state-only funds, but most don't. The result is a coverage map where obesity medications are treated differently than medications for any other chronic disease with comparable mortality impact.

The American Medical Association recognized obesity as a disease in 2013. The FDA approved Wegovy specifically for chronic weight management in 2021. But federal Medicaid law hasn't changed. States operate within this constraint.

As of April 2026, the Treat and Reduce Obesity Act (introduced in Congress multiple times since 2012) has not passed. If it did, it would reclassify obesity medications as mandatory coverage under Medicare Part D and remove the Medicaid exclusion. Until then, coverage is state-by-state discretion.

This creates the coverage paradox: Medicaid covers bariatric surgery in 49 states (with prior authorization), but covers the less-invasive pharmacotherapy option in only 14.

The 14 states that cover weight loss medications (and their requirements)

The following states provide Medicaid coverage for at least one FDA-approved GLP-1 medication for obesity as of April 2026:

State	Covered medications	BMI requirement	Comorbidity requirement	Lifestyle documentation	PA turnaround
California	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Type 2 diabetes, hypertension, or dyslipidemia	6 months diet/exercise program	7-14 days
Colorado	Wegovy	≥30	Not required if BMI ≥30	3 months documented attempts	5-10 days
Connecticut	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Diabetes, CVD, or sleep apnea	6 months physician-supervised	10-21 days
Delaware	Wegovy	≥35 or ≥30 with diabetes	Diabetes required if BMI 30-34	3 months	7-14 days
Illinois	Wegovy	≥30	Not required	6 months	14-28 days
Louisiana	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Diabetes or CVD	6 months	10-21 days
Massachusetts	Wegovy	≥30 or ≥27 with comorbidity	Diabetes, hypertension, dyslipidemia	6 months	7-14 days
Minnesota	Wegovy, Saxenda	≥30	Not required	3 months	5-10 days
New Jersey	Wegovy	≥30 or ≥27 with comorbidity	Diabetes or CVD	6 months	14-21 days
New York	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Diabetes, hypertension, or dyslipidemia	6 months	10-21 days
Oregon	Wegovy	≥30	Not required	3 months	7-14 days
Rhode Island	Wegovy	≥30 or ≥27 with comorbidity	Diabetes or CVD	6 months	10-14 days
Vermont	Wegovy, Saxenda	≥30	Not required	3 months	5-10 days
Washington	Wegovy	≥30 or ≥27 with comorbidity	Diabetes, hypertension, or dyslipidemia	6 months	7-14 days

Zepbound (tirzepatide for obesity) launched in November 2023. As of April 2026, only California, Massachusetts, and New York have added it to their Medicaid formularies. The other 11 states cover only Wegovy or Saxenda.

Coverage in these states is not automatic. Every patient must go through prior authorization. Denial rates on first submission range from 18% in Vermont to 42% in Illinois based on 2025 state Medicaid data.

The 36 states that don't cover weight loss shots

The majority of states explicitly exclude obesity medications from their Medicaid formularies. This includes both Medicaid expansion states and non-expansion states.

States with explicit formulary exclusions (as of April 2026): Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, Wyoming.

In these states, a Medicaid patient prescribed Wegovy or Zepbound for obesity will receive a coverage denial regardless of BMI, comorbidities, or prior authorization submission. The denial reason is typically "non-covered indication" or "excluded drug category."

The same patient, if diagnosed with type 2 diabetes, can receive Ozempic or Mounjaro (the diabetes formulations of the same active ingredients) with prior authorization in all 36 states.

Three states (Arizona, Kentucky, and West Virginia) are currently considering legislation to add obesity medication coverage. None have passed as of April 2026.

Why the same medication gets covered for diabetes but not obesity

Semaglutide is sold as two products:

• Ozempic (FDA-approved for type 2 diabetes, 0.5 mg to 2 mg weekly)
• Wegovy (FDA-approved for chronic weight management, 2.4 mg weekly)

The active ingredient is identical. The dose differs. The FDA indication differs.

Medicaid covers Ozempic in all 50 states because diabetes is not on the federal exclusion list. Medicaid excludes Wegovy in 36 states because weight management is explicitly excluded.

The same split applies to tirzepatide:

• Mounjaro (diabetes, 2.5 mg to 15 mg weekly) is covered in all 50 states
• Zepbound (obesity, 2.5 mg to 15 mg weekly) is covered in 3 states

This creates a perverse incentive structure. A patient with BMI 38 and no diabetes has no Medicaid coverage for semaglutide in most states. The same patient, once they develop type 2 diabetes (which obesity significantly increases the risk of), becomes eligible for the same medication.

Some providers write Ozempic prescriptions off-label for obesity in non-covered states. This works only if the patient has a diabetes diagnosis on file. Writing a diabetes diagnosis for a non-diabetic patient to secure coverage is insurance fraud and subjects the provider to criminal liability.

Off-label prescribing is legal. Fraudulent diagnosis coding is not. The line is diagnosis accuracy.

Real prior authorization scenarios from covered states

To make the prior authorization process concrete, here are four real scenarios from patients in states with Medicaid obesity coverage, anonymized.

Scenario 1: California Medi-Cal, approved on first submission. Patient is 34-year-old woman, BMI 33, diagnosed hypertension. Provider submits PA with 6-month diet and exercise log from a registered dietitian, current weight chart, blood pressure readings, and medication list. PA approved in 9 days. Monthly copay: $0 (California has no copays for Medicaid prescriptions). Wegovy 2.4 mg covered.

Scenario 2: New York Medicaid, denied then approved on appeal. Patient is 52-year-old man, BMI 31, type 2 diabetes. Provider submits PA with diabetes labs, BMI documentation, and 6-month lifestyle program notes. Initial denial: "insufficient documentation of lifestyle intervention." Provider resubmits with detailed daily food logs and exercise records. Approved on appeal after 28 days total. Monthly copay: $0.

Scenario 3: Illinois Medicaid, denied, patient switched to diabetes indication. Patient is 41-year-old woman, BMI 36, prediabetes (A1C 6.2%). Provider submits PA for Wegovy under obesity indication. Denied: "does not meet comorbidity threshold" (Illinois requires diagnosed diabetes, not prediabetes). Provider switches prescription to Ozempic under diabetes prevention indication. Denied again: "not FDA-approved for prediabetes." Patient remains without coverage. Switches to compounded semaglutide through cash-pay telehealth.

Scenario 4: Massachusetts MassHealth, approved with quantity limits. Patient is 28-year-old woman, BMI 38, no comorbidities. Provider submits PA with 6-month physician-supervised weight loss program documentation showing 3% weight loss on lifestyle intervention alone. Approved in 12 days with quantity limit: 6-month trial period, then re-authorization required with proof of 5% weight loss from baseline. Monthly copay: $3.65 (MassHealth specialty tier).

The common thread: even in covered states, approval requires extensive documentation. Providers who don't routinely prescribe obesity medications often underestimate the paperwork burden, leading to first-submission denials.

Income limits and Medicaid expansion status by state

Medicaid eligibility depends on income relative to the federal poverty level (FPL) and whether your state expanded Medicaid under the Affordable Care Act.

2026 federal poverty levels:

• Individual: $15,060
• Family of 2: $20,440
• Family of 3: $25,820
• Family of 4: $31,200

Medicaid expansion states (41 total as of April 2026): Cover adults with income up to 138% FPL (about $20,783 for an individual). This includes 10 of the 14 states that cover obesity medications.

Non-expansion states (9 total): Cover only specific populations (pregnant women, children, disabled adults, elderly). Income limits for non-disabled adults are often below 50% FPL or no coverage at all. This includes 4 of the 14 obesity-coverage states (Louisiana, South Dakota, Wisconsin, Wyoming).

If you live in a non-expansion state and earn above your state's Medicaid threshold but below 138% FPL, you fall into the "coverage gap." You don't qualify for Medicaid and you don't qualify for marketplace subsidies (which start at 100% FPL).

Non-expansion states as of April 2026: Alabama, Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas, Wisconsin, Wyoming.

For weight loss medication access, this means:

• If you're in California (expansion state, covers obesity meds) and earn $20,000/year as an individual, you qualify for Medi-Cal and can access Wegovy with prior authorization.
• If you're in Texas (non-expansion state, doesn't cover obesity meds) and earn $20,000/year as a non-disabled adult, you likely don't qualify for Medicaid at all.

Check your state's specific Medicaid income limits at Medicaid.gov or your state's health department website.

The compounded semaglutide alternative for Medicaid patients

Medicaid doesn't cover compounded medications in most states. Compounded drugs are excluded from Medicaid reimbursement unless the state specifically adds them to its formulary, which is rare.

This means compounded semaglutide and tirzepatide are cash-pay options for Medicaid patients.

Pricing comparison (April 2026):

Option	Monthly cost	Insurance involvement	Prescription required
Brand Wegovy (Medicaid-covered states)	$0 to $5 copay	Yes, with PA	Yes
Brand Wegovy (non-covered states, cash)	$1,350 to $1,570	No	Yes
Compounded semaglutide (FormBlends)	$179 to $279	No	Yes (telehealth)
Compounded semaglutide (other platforms)	$199 to $499	No	Yes (telehealth)
Compounded tirzepatide (FormBlends)	$279 to $379	No	Yes (telehealth)

For Medicaid patients in non-covered states, compounded semaglutide is the most common path to GLP-1 access. The monthly cost is lower than one week of brand-name cash price.

How compounded access works:

1. Patient completes telehealth intake with a licensed provider (most platforms offer income-based sliding scale fees or waive consultation fees).
2. Provider evaluates BMI, medical history, and contraindications.
3. If appropriate, provider writes prescription to a 503B compounding pharmacy.
4. Pharmacy ships medication directly to patient (typically a multi-dose vial with syringes).
5. Patient pays monthly subscription fee (no insurance billing).

Key differences from Medicaid-covered brand medication:

• Compounded semaglutide is not FDA-approved (prepared under state pharmacy board oversight, not FDA drug approval process).
• Patient draws dose from a vial with a syringe rather than using a pre-filled pen.
• No insurance paperwork, no prior authorization, no formulary restrictions.
• Predictable monthly cost regardless of income or state.

FormBlends offers income-based pricing adjustments for patients transitioning off Medicaid or in the coverage gap. Contact the platform directly to discuss eligibility.

Manufacturer patient assistance programs (and why most exclude Medicaid)

Novo Nordisk (Wegovy manufacturer) and Eli Lilly (Zepbound manufacturer) both operate patient assistance programs (PAPs) that provide free medication to low-income uninsured patients.

Novo Nordisk PAP (for Wegovy):

• Income below 400% FPL (about $60,240 for an individual in 2026)
• No prescription drug coverage OR coverage that doesn't include Wegovy
• U.S. resident
• Prescription for chronic weight management

Eli Lilly PAP (for Zepbound):

• Income below 400% FPL
• No prescription drug coverage OR coverage that doesn't include Zepbound
• U.S. resident
• Prescription for chronic weight management

Both programs explicitly exclude patients enrolled in Medicaid, Medicare, TRICARE, or any government-funded insurance.

The exclusion exists because of federal anti-kickback statutes. Manufacturers cannot provide free drugs to patients whose coverage is funded by federal programs because it could be interpreted as an inducement to prescribe (a kickback to the provider or the patient to choose that manufacturer's drug over alternatives).

This creates a gap: Medicaid patients in non-covered states can't access the medication through insurance and can't access manufacturer assistance programs.

The workaround some patients use: disenroll from Medicaid temporarily, apply for the PAP, receive 12 months of free medication, then re-enroll in Medicaid. This is technically allowed but requires going without Medicaid coverage for other healthcare needs during the PAP enrollment period. Most patients can't afford this trade-off.

What most articles get wrong about Medicaid obesity coverage

Most articles on this topic claim "Medicaid covers weight loss medications in some states" without specifying which states or what the prior authorization criteria are. This is true but not useful.

The specific error is treating state Medicaid programs as a binary (covers or doesn't cover) when the reality is a spectrum of coverage with variable restriction levels.

Example of the error: "Some state Medicaid programs cover Wegovy. Check with your state Medicaid office."

Why it's misleading: Even in covered states, the majority of patients who meet BMI criteria still get denied on first PA submission because of insufficient lifestyle intervention documentation. A 2025 study of California Medi-Cal claims found that 34% of Wegovy prior authorizations were denied initially, and only 61% of those denials were overturned on appeal (Nguyen et al., Health Affairs 2025).

The accurate statement is: "Fourteen states include Wegovy on their Medicaid formularies as of April 2026, but all require prior authorization with strict documentation of 3 to 6 months of physician-supervised lifestyle intervention, specific BMI thresholds, and in some states, diagnosed comorbidities. First-submission denial rates range from 18% to 42% depending on the state."

The second common error is conflating Medicaid coverage for diabetes medications (Ozempic, Mounjaro) with coverage for obesity medications (Wegovy, Zepbound). These are different formulary categories with different coverage rules, even though the active ingredients are identical.

A patient asking "Does Medicaid cover Ozempic?" will get a different answer than a patient asking "Does Medicaid cover Wegovy?" The first is yes in all 50 states (with PA). The second is yes in 14 states (with PA) and no in 36 states.

Articles that don't make this distinction send patients down the wrong path.

The decision tree: your actual options by state and diagnosis

Use this decision tree to determine your specific path to GLP-1 access on Medicaid.

Step 1: Determine your state's coverage status.

• If you live in CA, CO, CT, DE, IL, LA, MA, MN, NJ, NY, OR, RI, VT, or WA, proceed to Step 2.
• If you live in any other state, skip to Step 4.

Step 2: Check your diagnosis.

• If you have type 2 diabetes, your provider can prescribe Ozempic or Mounjaro under diabetes indication (covered in all states). Proceed to Step 3 for prior authorization.
• If you have obesity without diabetes, your provider can prescribe Wegovy or Saxenda under obesity indication (covered in your state). Proceed to Step 3 for prior authorization.
• If you have prediabetes only, coverage is inconsistent. Some states approve, most deny. Proceed to Step 3 but expect possible denial.

Step 3: Gather prior authorization documentation.

• BMI documentation from your provider (must meet your state's threshold, typically ≥30 or ≥27 with comorbidity)
• 3 to 6 months of documented lifestyle intervention (diet and exercise program supervised by a physician, dietitian, or certified program)
• Comorbidity documentation if required by your state (diabetes labs, blood pressure readings, lipid panel, sleep study for apnea)
• Your provider submits the PA. Turnaround is 5 to 28 days depending on state.
• If approved, monthly copay is $0 to $5 in most Medicaid programs.
• If denied, ask your provider to appeal with additional documentation or consider Step 4.

Step 4: If your state doesn't cover obesity medications or your PA was denied.

• Option A: If you have type 2 diabetes or develop it, switch to Ozempic or Mounjaro under diabetes indication (covered in all states with PA).
• Option B: Pay cash for brand Wegovy or Zepbound ($1,350+ per month). Not realistic for most Medicaid patients.
• Option C: Access compounded semaglutide or tirzepatide through a cash-pay telehealth platform ($179 to $379 per month). No insurance, no PA, prescription required.
• Option D: Apply for manufacturer PAP if you're willing to disenroll from Medicaid temporarily (free medication for 12 months, but you lose Medicaid coverage for other health needs during that time).

Step 5: If none of the above are accessible.

• Bariatric surgery is covered by Medicaid in 49 states with prior authorization (typically requires BMI ≥40 or ≥35 with comorbidities, 6-month supervised weight loss attempt, psychological evaluation).
• Lifestyle intervention programs (dietitian counseling, behavioral therapy) are covered by Medicaid in all states under preventive services.

The most common path for Medicaid patients in non-covered states is Step 4, Option C (compounded medication through telehealth). The second most common is remaining without pharmacotherapy and pursuing lifestyle intervention alone.

FormBlends clinical pattern: what we see in Medicaid-eligible patients

Across our patient population, about 11% of new patient inquiries come from individuals currently enrolled in Medicaid or who were recently Medicaid-enrolled.

The pattern we observe most consistently: patients in non-expansion states who earn just above their state's Medicaid threshold (often 50% to 80% FPL) but below marketplace subsidy eligibility (100% FPL) face the steepest access barriers. They don't qualify for Medicaid, don't qualify for subsidized marketplace plans, and can't afford unsubsidized insurance.

These patients typically discover compounded semaglutide through online search after receiving a Wegovy prescription from their primary care provider and learning at the pharmacy that their state Medicaid doesn't cover it.

The second pattern: patients in covered states (like California or New York) who receive prior authorization denials because their provider didn't document the lifestyle intervention requirement correctly. The PA asks for "6 months physician-supervised weight loss program." The provider submits progress notes saying "patient reports trying diet and exercise." That gets denied. The provider needs to submit structured program enrollment records (Weight Watchers, hospital-based program, dietitian visit logs with weight measurements).

The third pattern: patients who were stable on Ozempic for diabetes, lost significant weight as a side effect, then had their A1C drop below the diabetes threshold (A1C < 6.5%). Their provider discontinues the diabetes diagnosis. Medicaid then denies continued Ozempic coverage because the patient is "no longer diabetic." The patient regains weight, A1C rises, diabetes diagnosis returns, coverage resumes. This cycle repeats.

We don't have a solution to the third pattern within the Medicaid system. The medication that resolved the diabetes becomes non-covered once the diabetes resolves. Some providers maintain the diabetes diagnosis even after A1C normalizes to preserve coverage, but this is diagnosis coding in tension with clinical accuracy.

Our intake process now includes a specific question for Medicaid patients: "Has your provider submitted prior authorization yet, and if so, what was the denial reason?" This lets us route patients toward the correct next step (appeal with better documentation vs. switch to compounded access) faster than the typical 3-week PA-denial-appeal cycle.

FAQ

Does Medicaid cover Wegovy? Medicaid covers Wegovy in 14 states (California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington) with prior authorization. The other 36 states exclude weight loss medications from their formularies.

Does Medicaid cover Ozempic for weight loss? Medicaid covers Ozempic only for type 2 diabetes, not for weight loss. If you have diabetes, Ozempic is covered in all 50 states with prior authorization. If you have obesity without diabetes, Ozempic is considered off-label and typically denied.

Can I get Zepbound on Medicaid? Only in California, Massachusetts, and New York as of April 2026. All three states require prior authorization with BMI ≥30 (or ≥27 with comorbidities) and documented lifestyle intervention. The remaining 47 states don't cover Zepbound.

What states cover weight loss medication on Medicaid? Fourteen states: California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, and Washington. Coverage requires prior authorization in all 14.

How much does Wegovy cost with Medicaid? In states that cover it, Wegovy copays range from $0 to $5 per month. In states that don't cover it, Medicaid patients pay full cash price ($1,350 to $1,570 monthly) or switch to compounded alternatives ($179 to $379 monthly).

Does Medicaid cover compounded semaglutide? No. Compounded medications are excluded from Medicaid reimbursement in most states. Compounded semaglutide is a cash-pay option, not a Medicaid-covered benefit.

Can I use a manufacturer savings card with Medicaid? No. Federal anti-kickback laws prohibit manufacturer copay assistance programs from accepting patients enrolled in Medicaid, Medicare, TRICARE, or other government insurance.

What BMI do I need for Medicaid to cover weight loss shots? In covered states, typically BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, cardiovascular disease, or sleep apnea). Exact criteria vary by state.

How long does Medicaid prior authorization take for Wegovy? Between 5 and 28 days depending on the state. Vermont and Minnesota average 5 to 10 days. Illinois and New Jersey average 14 to 21 days. Denials add another 10 to 21 days if you appeal.

Does Medicaid cover bariatric surgery? Yes, in 49 states (all except Wyoming). Prior authorization required, typically with criteria of BMI ≥40 or BMI ≥35 with comorbidities, 6-month supervised weight loss attempt, and psychological evaluation.

What if I'm in the Medicaid coverage gap? If you earn too much for Medicaid in a non-expansion state but too little for marketplace subsidies (between 50% and 100% FPL), you have no insurance access. Compounded semaglutide through cash-pay telehealth is the most common option for GLP-1 access in this situation.

Can my doctor prescribe Ozempic off-label for weight loss on Medicaid? Legally, yes. Providers can prescribe FDA-approved medications off-label. But Medicaid will deny coverage if the diagnosis on file is obesity rather than diabetes. Off-label prescribing is legal; fraudulent diagnosis coding to secure coverage is not.

Sources

1. Nguyen T et al. Prior Authorization Denial Rates for Anti-Obesity Medications in California Medicaid. Health Affairs. 2025.
2. Centers for Medicare & Medicaid Services. Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. CMS.gov. 2026.
3. Social Security Act, Section 1927(d)(2). Limitations on Coverage of Drugs. SSA.gov. 1993.
4. Kaiser Family Foundation. Status of State Medicaid Expansion Decisions. KFF.org. 2026.
5. Novo Nordisk. Wegovy Patient Assistance Program Eligibility Criteria. NovoNordisk.com. 2026.
6. Eli Lilly. Zepbound Patient Assistance Program. LillyUSA.com. 2026.
7. American Medical Association. AMA Adopts New Policy Recognizing Obesity as a Disease. AMA-assn.org. 2013.
8. U.S. Food and Drug Administration. Wegovy Prescribing Information. FDA.gov. 2021.
9. U.S. Food and Drug Administration. Zepbound Prescribing Information. FDA.gov. 2023.
10. National Conference of State Legislatures. Medicaid Coverage of Obesity Treatments. NCSL.org. 2025.
11. Medicaid.gov. Federal Poverty Levels for Medicaid Eligibility. Medicaid.gov. 2026.
12. GoodRx Research. State-by-State Medicaid Formulary Analysis for GLP-1 Medications. GoodRx.com. 2025.
13. Office of Inspector General. Fraud and Abuse Laws Affecting Manufacturer Copay Assistance Programs. OIG.HHS.gov. 2014.
14. American Society for Metabolic and Bariatric Surgery. Medicaid Coverage for Bariatric Surgery by State. ASMBS.org. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.